Showing results (71-80 of 92) with videos related to
Sort By:
Pageof 10
Synapse (New York, N.Y.)|January 1, 1990
Pargyline-sensitive selective accumulation of a radiolabeled MPTP analog in the primate cerebral cortex and basal gangliaS M Efange, H F Kung, D C Mash, et al.The American Journal of Cardiology|October 1, 1994
Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse)S Chakko, S Sepulveda, K M Kessler, et al.Journal of Neuropathology and Experimental Neurology|December 23, 1998
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individualsC M Hulette, K A Welsh-Bohmer, M G Murray, et al.Annals of the New York Academy of Sciences|July 21, 1998
Medication development of ibogaine as a pharmacotherapy for drug dependenceD C Mash, C A Kovera, B E Buck, et al.Journal of Analytical Toxicology|October 1, 1996
Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuascaJ C Callaway, L P Raymon, W L Hearn, et al.Annals of Neurology|April 1, 1997
Immunochemical analysis of dopamine transporter protein in Parkinson's diseaseG W Miller, J K Staley, C J Heilman, et al.Acta Neurologica Scandinavica|March 4, 2009
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's diseaseJ Pablo, S A Banack, P A Cox, et al.Experimental Neurology|April 8, 1999
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's diseaseG W Miller, J D Erickson, J T Perez, et al.Psychopharmacology|September 1, 1996
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaineJ K Staley, Q Ouyang, J Pablo, et al.Annals of the New York Academy of Sciences|November 21, 2000
Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measuresD C Mash, C A Kovera, J Pablo, et al.Pageof 10